Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

CHRS Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Coherus Oncology, Inc.NASDAQ: CHRS

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt remains negative

Q1 FY2026 short-term debt was $1.9M, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 0.7% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
  • Short-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.9M— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Short-term Debt vs competitors

How CHRS compares with its peers on the latest reported figures

  • CHRS's Mar 2026 short-term debt of $1.9M is the 4th highest of the 11 companies compared; the peer median is $164K.
  • Short-term debt amounts to 0.7% of total assets for CHRS, versus a peer median of 0.2%.
CHRS Competitors Peer median
Short-term Debt for CHRS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CCCCC4 Therapeutics, Inc.Mar 2026$6.52M ——2.0%
OABIOmniAb, Inc.Mar 2026$3.94M ——1.3%
CDXSCodexis, Inc.Mar 2026$3.3M ——2.6%
CHRSCoherus Oncology, Inc.Mar 2026$1.9M ——0.7%
PLXProtalix BioTherapeutics, Inc.Mar 2026$1.43M ——1.4%
AVTXAvalo Therapeutics, Inc.Mar 2026$328K ——0.3%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$0 -100.0%—0.0%
IVVDInvivyd, Inc.Mar 2026$0 ——0.0%
TARAProtara Therapeutics, Inc.Mar 2026$0 ——0.0%
IMDXInsight Molecular Diagnostics Inc.Mar 2026$0 ——0.0%
SGMOSangamo Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding CHRS) $164K-100.0%—0.2%

Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents417.2M63.55M102.89M125.99M88.88M
Short-term Investments0128.13M14.86M083.25M
Net Receivables123.02M109.96M260.52M122.33M18.42M
Inventory37.64M38.79M62.61M70.09M3.17M
Other Current Assets10.8M22.92M11.1M11.53M6.23M
Total Current Assets602.32M381.23M475.63M341.58M206.71M
Property, Plant & Equipment (Net)7.81M8.75M5.12M2.84M1.35M
Goodwill943K943K943K00
Intangible Assets2.62M4.99M70.73M53.65M46.24M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets65.64M84.93M77.18M50.47M4.05M
Total Non-current Assets77.01M99.61M153.97M106.95M51.64M
Total Assets679.33M480.85M629.6M448.53M258.34M
Account Payables16.16M11.53M35.22M28.46M9.92M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities22.01M22.61M21.52M33.11M16.07M
Total Current Liabilities165.33M138.69M331.77M282.98M141.88M
Long-term Debt408.28M471.06M473.37M264.93M37.05M
Deferred Tax Liabilities001.1M1.1M1.1M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities750K3.47M11.46M28.23M15.84M
Total Non-current Liabilities416.28M479.57M491.26M297.54M55.45M
Total Liabilities581.61M618.27M823.03M580.52M197.33M
Common Stock7K8K11K12K12K
Retained Earnings(1.05B)(1.34B)(1.58B)(1.55B)(1.38B)
Accumulated OCI(270K)(249K)(248K)(275K)(195K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity97.73M(137.42M)(193.43M)(131.99M)61.01M
Total Debt419.02M480.42M480.84M269.9M40.34M
Net Debt1.83M416.88M377.95M143.92M(48.54M)

Coherus Oncology, Inc.

NASDAQ:CHRS

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.